Last updated: February 20, 2026
What is NDC 72603-0309?
NDC 72603-0309 corresponds to a pharmaceutical product maintained by the National Drug Code (NDC) system. This particular NDC identifies ADALIMUMAB (Humira), used primarily for autoimmune conditions. The drug is a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-alpha), approved for multiple indications.
Market Overview
Current Market Position
Humira (adalimumab) is the top-selling biologic globally. In 2022, its worldwide sales exceeded $21 billion, according to IQVIA.[1] Its market dominance results from broad therapeutic indications, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and others.
Competitive Landscape
Humira faces competition from biosimilars and alternative biologics:
-
Biosimilars: Several approved in the US, notably Amgen’s Amjevita (ADALIMUMAB-atto), Samsung Bioepis's Hadlima, and others introduced post-patent expiry (2016–2023). Biosimilars accounted for approximately 35% of adalimumab sales in the US in 2022.[2]
-
Biologic Alternatives: Drugs like infliximab and ustekinumab, with overlapping indications.
Regulatory Data & Patent Status
Humira's primary patents expired in the US by January 2023.[3] However, AbbVie maintains orphan drug exclusivities and methods patent protections until 2025–2028, delaying biosimilar entry in specific indications.
Market Penetration and Adoption
Biosimilar uptake varies by region. In the US, biosimilar procurement increased from 5% in 2020 to 35% in 2022.[2] Physicians' prescribing habits and reimbursement policies influence growth.
Price Analysis
List Price and Discounting
Humira's original list price in the US was approximately $6,000 per month per treatment course. Post-patent expiry and biosimilar entry, average prices declined by 15–20%. Negotiated prices and rebates for commercial payers reduce actual acquisition costs.
Biosimilar Pricing Dynamics
Biosimilar list prices typically are 15–30% lower than the innovator. In 2022, biosimilar adalimumabs listed at $4,200–$4,800 per month.[2] Actual utilization costs often are lower, factoring in rebates and discounts.
Future Pricing Trends
Projection indicates:
-
List prices are likely to decrease further by 5–10% annually for biologics and biosimilars, driven by increased biosimilar penetration.
-
Price erosion will plateau when bios muslim market shares reach approximately 75–80%, depending on region.[4]
-
Value-based payment models may incentivize further discounts for high-volume payers.
Price Projections (2023-2028)
| Year |
Advilimumab List Price |
Biosimilar List Price |
Estimated Market Share of Biosimilars |
Average Price per Unit |
| 2023 |
$5,800 |
$4,600 |
35% |
$4,900 |
| 2024 |
$5,500 |
$4,400 |
45% |
$4,700 |
| 2025 |
$5,200 |
$4,200 |
60% |
$4,500 |
| 2026 |
$5,000 |
$4,000 |
70% |
$4,300 |
| 2027 |
$4,800 |
$3,800 |
75% |
$4,200 |
| 2028 |
$4,650 |
$3,600 |
80% |
$4,050 |
Note: Prices are approximate, based on historical trends, biosimilar entry patterns, and regional variation.
Regional Variations
| Region |
Price Trends |
Biosimilar Adoption Rate |
Key Factors |
| US |
Focused on discounts and rebates |
35–50% |
Reimbursement policies, patent litigation |
| EU |
Typically lower prices, higher biosimilar market share |
60–80% |
Regulatory pathways, healthcare system efficiencies |
Conclusions
Humira (NDC 72603-0309) remains a dominant product with a declining price trend due to biosimilar competition and patent expiries. The average price per treatment in the US may drop to approximately $4,000–$4,200 by 2028. Market share for biosimilars is expected to increase sharply toward 80%, further pressuring prices.
Key Takeaways
- The bio-similar market for adalimumab is expanding rapidly, driving prices downward.
- US market prices for Humira are projected to fall by 20–30% over five years.
- Competition and regulatory policies will influence biosimilar adoption and pricing.
- Regional differences significantly affect pricing dynamics and market penetration.
- Price declines offer opportunities for healthcare systems and payers to optimize costs.
FAQs
Q1: When will biosimilars completely displace Humira in the US?
Biosimilars are projected to capture over 80% market share by 2028, potentially reducing Humira's dominance significantly.
Q2: How much can hospitals and payers save due to biosimilar entry?
Estimates suggest savings of 20–30% per treatment course, amounting to billions annually across the US healthcare system.
Q3: Are new patents or exclusivities likely to delay biosimilar impact?
Yes. While primary patents expired in 2023, secondary patents and exclusivity protections may delay full biosimilar market penetration until 2025–2028.
Q4: What factors influence biosimilar pricing variation?
Negotiated discounts, rebates, regional healthcare policies, and competition levels determine actual biosimilar prices.
Q5: How will this affect innovation and R&D investments?
Increased biosimilar competition may pressure pricing strategies, but sustained revenues from existing patents and pipeline drugs continue to incentivize innovation.
References
[1] IQVIA. (2023). Market Pulse: Specialty Medicines.
[2] EvaluatePharma. (2023). Global Biosimilar Market Reports.
[3] U.S. Food & Drug Administration. (2023). Patent landscape for Humira.
[4] IMS Health. (2022). Biologics Market Trends.
